Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Receivables (2019 - 2025)

Inmune Bio's Receivables history spans 7 years, with the latest figure at $2.5 million for Q3 2025.

  • For Q3 2025, Receivables rose 48.97% year-over-year to $2.5 million; the TTM value through Sep 2025 reached $2.5 million, up 48.97%, while the annual FY2024 figure was $1.4 million, 42.3% down from the prior year.
  • Receivables for Q3 2025 was $2.5 million at Inmune Bio, down from $2.6 million in the prior quarter.
  • Across five years, Receivables topped out at $3.7 million in Q2 2024 and bottomed at $100000.0 in Q1 2021.
  • The 5-year median for Receivables is $904500.0 (2021), against an average of $1.2 million.
  • The largest annual shift saw Receivables tumbled 96.55% in 2021 before it soared 100.0% in 2022.
  • A 5-year view of Receivables shows it stood at $400000.0 in 2021, then crashed by 75.0% to $100000.0 in 2022, then soared by 2342.0% to $2.4 million in 2023, then tumbled by 42.3% to $1.4 million in 2024, then soared by 74.88% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Receivables are $2.5 million (Q3 2025), $2.6 million (Q2 2025), and $1.4 million (Q1 2025).